Sarah Y Wu, Andrea Giannini, Marlene Girardo, Alessandra Schmitt, Javier F Magrina, Kristina Butler
{"title":"Malignant Transformation of Squamous Cell Carcinoma in Mature Cystic Teratoma of the Ovary: A Systematic Review and Meta-Analysis of Data.","authors":"Sarah Y Wu, Andrea Giannini, Marlene Girardo, Alessandra Schmitt, Javier F Magrina, Kristina Butler","doi":"10.1159/000542672","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Mature cystic teratomas (MCTs) are the most common neoplasm of the ovary, occurring in 10-20% of women during their lifetimes. MCTs may rarely undergo malignant transformation, of which squamous cell carcinoma is the most common histopathology. This rare malignancy is poorly understood; therefore, medical and surgical treatment have yet to be optimized to produce the best outcomes for patients diagnosed with squamous cell carcinoma in MCT (SCC-MCT). We aimed to characterize the clinicopathologic features, surgical treatment, adjuvant treatment, and prognosis of SCC-MCT.</p><p><strong>Methods: </strong>A systematic literature search was performed using MEDLINE through Ovid and PubMed for relevant articles on malignant transformation of squamous cell carcinoma in MCT of the ovary. 155 studies were identified, yielding clinical information on 654 unique patients. Univariate and multivariate analyses were performed to assess factors influencing overall survival (OS). Disease-free survival and OS of cases with follow-up were assessed by the Kaplan-Meier life table analysis. Survival rates were assessed with the log-rank test.</p><p><strong>Results: </strong>We found that SCC-MCT generally presented in postmenopausal patients with tumor sizes greater than 10 cm. Patients diagnosed with FIGO stage I disease had better survival than later stage disease, and higher FIGO stage was independently associated with worse OS. Longer OS was associated with younger age at diagnosis, low preoperative levels of SCC Ag and CA-125, and treatment with lymphadenectomy. Chemotherapy or radiotherapy were not associated with improved survival.</p><p><strong>Conclusion: </strong>The prognosis of SCC-MCT is dependent on a variety of factors including age, serum tumor marker levels, and surgical treatment. Prognosis regardless of adjuvant treatment modality chosen for late-stage malignancy is generally poor. Future research focusing on collecting patient outcome data from international centers is needed to better guide treatment choices.</p>","PeriodicalId":12952,"journal":{"name":"Gynecologic and Obstetric Investigation","volume":" ","pages":"1-13"},"PeriodicalIF":2.0000,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecologic and Obstetric Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000542672","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Mature cystic teratomas (MCTs) are the most common neoplasm of the ovary, occurring in 10-20% of women during their lifetimes. MCTs may rarely undergo malignant transformation, of which squamous cell carcinoma is the most common histopathology. This rare malignancy is poorly understood; therefore, medical and surgical treatment have yet to be optimized to produce the best outcomes for patients diagnosed with squamous cell carcinoma in MCT (SCC-MCT). We aimed to characterize the clinicopathologic features, surgical treatment, adjuvant treatment, and prognosis of SCC-MCT.
Methods: A systematic literature search was performed using MEDLINE through Ovid and PubMed for relevant articles on malignant transformation of squamous cell carcinoma in MCT of the ovary. 155 studies were identified, yielding clinical information on 654 unique patients. Univariate and multivariate analyses were performed to assess factors influencing overall survival (OS). Disease-free survival and OS of cases with follow-up were assessed by the Kaplan-Meier life table analysis. Survival rates were assessed with the log-rank test.
Results: We found that SCC-MCT generally presented in postmenopausal patients with tumor sizes greater than 10 cm. Patients diagnosed with FIGO stage I disease had better survival than later stage disease, and higher FIGO stage was independently associated with worse OS. Longer OS was associated with younger age at diagnosis, low preoperative levels of SCC Ag and CA-125, and treatment with lymphadenectomy. Chemotherapy or radiotherapy were not associated with improved survival.
Conclusion: The prognosis of SCC-MCT is dependent on a variety of factors including age, serum tumor marker levels, and surgical treatment. Prognosis regardless of adjuvant treatment modality chosen for late-stage malignancy is generally poor. Future research focusing on collecting patient outcome data from international centers is needed to better guide treatment choices.
期刊介绍：
This journal covers the most active and promising areas of current research in gynecology and obstetrics. Invited, well-referenced reviews by noted experts keep readers in touch with the general framework and direction of international study. Original papers report selected experimental and clinical investigations in all fields related to gynecology, obstetrics and reproduction. Short communications are published to allow immediate discussion of new data. The international and interdisciplinary character of this periodical provides an avenue to less accessible sources and to worldwide research for investigators and practitioners.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
